Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...

Sensorion's Audiogene Phase I/II trial of the SENS-501 gene therapy programme has received a favourable recommendation from ...

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

MeiraGTx’s investigational gene therapy AAV-AIPL1 has improved the sight of 11 children who were born blind. MeiraGTx is ...

Revolutionary gene therapy approaches show promise in treating various retinal conditions, potentially transforming treatment ...

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle and SK Capital Partners at a discount, ending ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

A Connecticut boy is among four children all born with severe childhood blindness who gained “life-changing improvements” to ...

In recent weeks, Children’s Hospital Los Angeles in East Hollywood has taken steps to improve care for some of its pediatric patients. In late January, ...

Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...